Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 5:56 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1969–1992 of 5,569 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Degenerative Conditions, Neurologic Clear all
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Effect of Equol Supplementation on Arterial Stiffness and Cognition in Healthy Volunteers

NCT05741060
View directory record Official record
Conditions
Arterial Stiffness, White Matter Lesions, Cognitive Decline
Interventions
S-equol, Placebo
Drug
Lead sponsor
Akira Sekikawa
Other
Eligibility
65 Years to 85 Years
Enrollment
369 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
3
States / cities
Atlanta, Georgia • Winston-Salem, North Carolina • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Nov 3, 2026, 5:56 AM EST
Completed Not applicable Interventional

Deep Brain Stimulation to Treat Symptoms of Parkinson's Disease

NCT00552474
View directory record Official record
Conditions
Parkinson Disease, Movement Disorders
Interventions
Libra Deep Brain Stimulation System
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years to 80 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
15
States / cities
Loma Linda, California • Gainesville, Florida • Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2019 · Synced Nov 3, 2026, 5:56 AM EST
Terminated Phase 1 Interventional Accepts healthy volunteers

Evaluation of [123I] MNI-340 and SPECT as a Marker of Beta-Amyloid Protein Deposition

NCT00968097
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
123-I MNI-340
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
50 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 3, 2019 · Synced Nov 3, 2026, 5:56 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

An Study to Determine the Bioavailability of E2609 Tablets Compared to Capsules and the Effect of Food on Absorption

NCT01716897
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
E2609
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
30 Years to 55 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated May 22, 2013 · Synced Nov 3, 2026, 5:56 AM EST
Completed Phase 1 Interventional

Leukine (Sargramostim) for Parkinson's Disease

NCT01882010
View directory record Official record
Conditions
Parkinson's Disease
Interventions
sargramostim, placebo, Sham Comparator: Controls
Drug · Diagnostic Test
Lead sponsor
University of Nebraska
Other
Eligibility
35 Years to 85 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
2
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 6, 2023 · Synced Nov 3, 2026, 5:56 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Test of A Model of Representational Knowledge Stored in the Human Prefrontal Cortex

NCT00024908
View directory record Official record
Conditions
Intracranial Central Nervous System Disorder, Mental Disorder, Healthy
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
6 Years to 90 Years
Enrollment
949 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Nov 3, 2026, 5:56 AM EST
Completed Not applicable Interventional

High-intensity Interval Circuit Training in People With Parkinson Disease

NCT06576817
View directory record Official record
Conditions
Parkinson Disease
Interventions
High intensity circuit exercise class - Lower and upper extremity, High intensity circuit exercise class - Lower extremity alone
Other
Lead sponsor
Pacific Northwest University of Health Sciences
Other
Eligibility
Not listed
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Yakima, Washington
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Nov 3, 2026, 5:56 AM EST
Completed Phase 3 Interventional Results available

Safety of Switching From Donepezil to Rivastigmine Patch in Patients With Probable Alzheimer's Disease

NCT00428389
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Rivastigmine 5 cm^2 transdermal patch, Rivastigmine 10 cm^2 transdermal patch
Drug
Lead sponsor
Novartis
Industry
Eligibility
50 Years and older
Enrollment
262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
23
States / cities
Sun City, Arizona • Costa Mesa, California • Fresno, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2014 · Synced Nov 3, 2026, 5:56 AM EST
Completed Phase 1 Interventional

Pharmacokinetics and Safety Study of LY03003 in Patients With Early-stage Parkinson's Disease

NCT02055274
View directory record Official record
Conditions
Parkinson's Disease
Interventions
LY03003, Neupro
Drug
Lead sponsor
Luye Pharma Group Ltd.
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
5
States / cities
Long Beach, California • Orlando, Florida • Douglasville, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2015 · Synced Nov 3, 2026, 5:56 AM EST
Active, not recruiting Phase 2 Interventional Results available

A Study of Lu AF82422 in Participants With Multiple System Atrophy

NCT05104476
View directory record Official record
Conditions
Multiple System Atrophy
Interventions
Lu AF82422, Placebo
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
40 Years to 75 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
16
States / cities
Fountain Valley, California • La Jolla, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Nov 3, 2026, 5:56 AM EST
Completed Phase 2 Interventional

Levetiracetam Treatment of L-dopa Induced Dyskinesias

NCT00076674
View directory record Official record
Conditions
Dyskinesias, Parkinson Disease
Interventions
Intravenous Levodopa
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 22, 2016 · Synced Nov 3, 2026, 5:56 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Compensatory Training to Support Brain Healthy Lifestyle Changes in Those at Risk for Alzheimer's Disease

NCT04118985
View directory record Official record
Conditions
Cognitive Symptom, Pre Senile Dementia, Alzheimer Disease
Interventions
Cognitive rehabilitation and health behavior change intervention, Self-implementation
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
50 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Nov 3, 2026, 5:56 AM EST
Completed Phase 3 Interventional Results available

Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia

NCT00105508
View directory record Official record
Conditions
Parkinson's Disease, Dyskinesia
Interventions
Sarizotan, Placebo
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
30 Years and older
Enrollment
506 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
31
States / cities
Birmingham, Alabama • Huntsville, Alabama • La Jolla, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2018 · Synced Nov 3, 2026, 5:56 AM EST
Terminated Phase 2 Interventional

AAB-001 (Bapineuzumab) Open-Label, Long-Term Extension Study in Patients With Mild to Moderate Alzheimer's Disease

NCT00606476
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Bapineuzumab (AAB-001)
Drug
Lead sponsor
JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Industry
Eligibility
Not listed
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
29
States / cities
Peoria, Arizona • Sun City, Arizona • Encino, California + 26 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2013 · Synced Nov 3, 2026, 5:56 AM EST
Recruiting No phase listed Observational

Multiple System Atrophy Multidisciplinary Clinic

NCT03811808
View directory record Official record
Conditions
Multiple System Atrophy (MSA)
Interventions
Not listed
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Nov 3, 2026, 5:56 AM EST
Completed Phase 2 Interventional

SNIFF 120: Study of Nasal Insulin to Fight Forgetfulness (120 Days)

NCT00438568
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer's Disease
Interventions
Regular Insulin, Placebo
Drug
Lead sponsor
University of Washington
Other
Eligibility
55 Years and older
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 14, 2012 · Synced Nov 3, 2026, 5:56 AM EST
Completed Phase 2 Interventional Results available

A Study of TAK-341 in Treatment of Multiple System Atrophy

NCT05526391
View directory record Official record
Conditions
Multiple System Atrophy
Interventions
Placebo, TAK-341
Drug
Lead sponsor
Takeda
Industry
Eligibility
40 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
7
States / cities
Farmington Hills, Michigan • Rochester, Minnesota • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Nov 3, 2026, 5:56 AM EST
Completed Not applicable Interventional

Lumbar Spine Muscle Degeneration Inhibits Rehabilitation-Induced Muscle Recovery

NCT03442374
View directory record Official record
Conditions
Disc Degeneration, Low Back Pain
Interventions
Exercise
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
21 Years to 85 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Nov 3, 2026, 5:56 AM EST
Terminated Phase 3 Interventional Results available

Arimoclomol in Amyotropic Lateral Sclerosis - Open Label Extension Trial

NCT03836716
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Arimoclomol
Drug
Lead sponsor
ZevraDenmark
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
7
States / cities
Phoenix, Arizona • Orange, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2023 · Synced Nov 3, 2026, 5:56 AM EST
Completed Phase 2 Interventional Results available

Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas

NCT03231306
View directory record Official record
Conditions
Neurofibromatosis Type 1, Plexiform Neurofibroma
Interventions
Binimetinib
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
1 Year and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
22
States / cities
Birmingham, Alabama • Los Angeles, California • Oakland, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 2, 2025 · Synced Nov 3, 2026, 5:56 AM EST
Terminated Phase 1 Interventional Results available

Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single Dose Administration Under Fasting Conditions in Prostate Cancer

NCT03478904
View directory record Official record
Conditions
Prostate Cancer
Interventions
Enzalutamide Liquid, Enzalutamide Capsule
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 10, 2021 · Synced Nov 3, 2026, 5:56 AM EST
Terminated Phase 3 Interventional Results available

Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled Seizures

NCT04485104
View directory record Official record
Conditions
Seizure in Participants With Tuberous Sclerosis Complex, Seizure in Participants With Dravet Syndrome, Seizure in Participants With Lennox-Gastaut Syndrome
Interventions
GWP42003-P
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
1 Month to 23 Months
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
6
States / cities
Little Rock, Arkansas • Los Angeles, California • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2025 · Synced Nov 3, 2026, 5:56 AM EST
Completed Phase 3 Interventional Results available

Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS)

NCT04577404
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
MT-1186
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
13
States / cities
Phoenix, Arizona • Rogers, Arkansas • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Nov 3, 2026, 5:56 AM EST
Completed Phase 4 Interventional Results available

Effectiveness of Antidepressant Treatment for Depression in People With Parkinson's Disease

NCT00304161
View directory record Official record
Conditions
Depressive Disorder, Parkinson Disease
Interventions
Atomoxetine, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
30 Years to 79 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Nov 3, 2026, 5:56 AM EST